• Tenosynovial Giant Cell Tumors (TGCT) are a group of benign tumors that involve the synovium, bursae and/or tendon sheath.
  • Although benign, these tumors can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint.
  • Surgery is the main treatment option; however, these tumors tends to recur, particularly in pigmented villonodular synovitis, a diffuse-type of TGCT. If untreated or if the tumor continually recurs damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability.
  • A genetic mutation in certain cells within the tumor causes overproduction of CSF-1, the ligand for the CSF1R receptor, which attracts macrophages and certain other cells that become the bulk of these tumors and cause the associated inflammatory changes.

Our Fight for Patients – Tenosynovial Giant Cell Tumors

A genetic mutation in patients with Tenosynovial Giant Cell Tumors is reported to result in over production of CSF-1.  Our goal at Deciphera is to inhibit CSF1R with DCC-3014 to combat the over production of CSF-1 and the associated inflammatory changes.